|
|
Volumn 355, Issue 6322, 2017, Pages 237-
|
|
A half-billion-dollar bid to head off emerging diseases
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EBOLA VACCINE;
MESSENGER RNA;
VACCINE;
VIRUS VECTOR;
VIRUS VACCINE;
GOVERNMENT;
IMMUNE RESPONSE;
MIDDLE EAST RESPIRATORY SYNDROME;
NATIONAL HEALTH ORGANIZATION;
NOTE;
PRIORITY JOURNAL;
PUBLIC HEALTH;
WORLD HEALTH ORGANIZATION;
COMMUNICABLE DISEASES, EMERGING;
CORONAVIRUS INFECTIONS;
ECONOMICS;
FINANCIAL MANAGEMENT;
GLOBAL HEALTH;
HENIPAVIRUS INFECTIONS;
HUMAN;
INVESTMENT;
LASSA FEVER;
VIROLOGY;
CAPITAL FINANCING;
COMMUNICABLE DISEASES, EMERGING;
CORONAVIRUS INFECTIONS;
GLOBAL HEALTH;
HENIPAVIRUS INFECTIONS;
HUMANS;
INVESTMENTS;
LASSA FEVER;
VIRAL VACCINES;
|
|
EID: 85010073086
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.355.6322.237 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|